Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Accu-Chek

- PMLiVE

New data could put Roche’s Tecentriq first in squamous lung cancer

NSCLC patients on the drug saw a reduced risk of disease progression

- PMLiVE

Mundipharma adds breast cancer biosimilar to its portfolio with Celltrion deal

Will launch Herzuma in seven European countries including the UK and Germany

- PMLiVE

MSD launches EU’s first biosimilar Herceptin in UK

Ontruzant is set to be strong competition for Roche’s blockbuster

Digital shakeout

Recent announcements by Nokia, Roche and others point to where digital health is heading

Roche Basel Switzerland

Roche wins European approval for bleeding disorder treatment Hemlibra

It's the first new medicine in over 20 years to treat patients with inhibitors

- PMLiVE

Novo’s oral semaglutide ‘safe and well-tolerated’

Releases first phase III data on the new version of its diabetes treatment

Roche Basel Switzerland

Roche to buy cancer data firm Flatiron for $1.9bn

Data provides a wealth of RWE opportunities

Roche Basel Switzerland

NICE backs Roche’s Gazyvaro after initial rejection

An undisclosed discount swayed the cost-effectiveness body

- PMLiVE

Roche’s lung drug Esbriet reserved for worse cases, says NICE

Boehringer Ingelheim’s Ofev subject to same conditions

- PMLiVE

Roche unveils data for Tecentriq/Avastin combo in kidney cancer

Patients on the combo had a lengthier PFS than those on Pfizer’s Sutent

Roche Basel Switzerland

Roche faces biosimilar blitz in 2018

Analysts predict copycat competitors will slow the Swiss group’s revenue growth

Roche Basel Switzerland

Roche’s autism drug scores FDA breakthrough status

Balovaptan could become the first drug to treat autism spectrum disorder

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links